General Notices

• Notice of Pre-Application Webinar and Frequently Asked Questions (FAQs) for RFA-DK-22-017 "NIDDK Information Network Coordinating Unit: dkNET-CU (U24 - Clinical Trial Not Allowed)"
  (NOT-DK-22-034)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Pre-Application Webinar for PAR-23-024, Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications (DP1- Clinical Trial Optional)
  (NOT-DK-23-004)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Consolidated Notice on NEI Clinical Trials Policies
  (NOT-EY-23-001)
  National Eye Institute
  

• Notice of Pre-Application Webinar for NIH Research Evaluation and Commercialization Hubs (REACH) Awards (RFA-OD-23-002)
  (NOT-OD-23-023)
  Office of the Director, NIH
  

• Intramural Loan Repayment Program for AIDS Research (AIDS-LRP)
  (NOT-OD-23-025)
  Office of the Director, NIH
  

• Intramural Loan Repayment Program for Clinical Researchers from Disadvantaged Backgrounds (CR-LRP)
  (NOT-OD-23-026)
  Office of the Director, NIH
  

• Intramural Loan Repayment Program for General Research (GR-LRP)
  (NOT-OD-23-027)
  Office of the Director, NIH
  

• Intramural Loan Repayment Program for General Research for ACGME Fellows (ACGME-LRP)
  (NOT-OD-23-028)
  Office of the Director, NIH
  

• Findings of Research Misconduct
  (NOT-OD-23-036)
  Office of the Director, NIH
  

• Request for Information (RFI): Innovative approaches to prevent mental health problems and promote mental wellness in populations that experience health disparities
  (NOT-OD-23-030)
  Office of Disease Prevention
  National Center for Complementary and Integrative Health
  National Institute of Biomedical Imaging and Bioengineering
  National Institute of Dental and Craniofacial Research
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  Office of Research on Women's Health
  

Notice of Changes to Funding Opportunities

• Notice of Early Expiration of NOT-AG-20-041 Notice of Special Interest: Advancing the Science of Geriatric Palliative Care
  (NOT-AG-22-047)
  National Institute on Aging
  

• Notice of Early Expiration of "Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI)", NOT-AI-21-008
  (NOT-AI-23-003)
  National Institute of Allergy and Infectious Diseases
  

• Notice of Participation of the National Eye Institute in PAR-22-105, "Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
  (NOT-EY-23-002)
  National Eye Institute
  

• Clarification of Eligibility for Institutions with Multiple Campuses in PAR-22-125 "National Institute of General Medical Sciences (NIGMS) Bridges to the Baccalaureate Research Training Program (T34)"
  (NOT-GM-23-008)
  National Institute of General Medical Sciences
  

• Clarification of Eligibility for Institutions with Multiple Campuses in PAR-21-198 "Bridges to the Doctorate Research Training Program (T32)"
  (NOT-GM-23-022)
  National Institute of General Medical Sciences
  

• Notice of NINR Participation in RFA-OD-22-015, "Galvanizing Health Equity Through Novel and Diverse Educational Resources (GENDER) Research Education (R25 Clinical Trial Not Allowed)
  (NOT-NR-23-002)
  National Institute of Nursing Research
  

• Notice of NINR Participation in NOT-EB-21-001 "Notice of Special Interest (NOSI): Small Business Initiatives for Innovative Diagnostic Technology for Improving Outcomes for Maternal Health"
  (NOT-NR-23-003)
  National Institute of Nursing Research
  

• Notice of Change to Key Dates for PAR-22-230 NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R01 Clinical Trial Optional)
  (NOT-NR-23-004)
  National Institute of Nursing Research
  

• Notice of Change to Key Dates for PAR-22-231 NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R21 Clinical Trial Optional)
  (NOT-NR-23-005)
  National Institute of Nursing Research
  

• Notice of NINDS Specific Interest in AD/ADRD for PAS-22-196 "Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)"
  (NOT-NS-23-049)
  National Institute of Neurological Disorders and Stroke
  

• Notice of NINDS Specific Interest in AD/ADRD for PAS-22-197 "Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)"
  (NOT-NS-23-050)
  National Institute of Neurological Disorders and Stroke
  

• Notice to Extend the Expiration Date for PAR-20-179 and PAR-20-180
  (NOT-OD-23-033)
  Office of Disease Prevention
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for NIH Medical Scientist Partnership Program (FM1 Clinical Trial Not Allowed)
  (NOT-AI-23-011)
  National Institute of Allergy and Infectious Diseases
  National Cancer Institute
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  

Notices of Special Interest

• Notice of Special Interest (NOSI): Advancing the Science of Geriatric Palliative Care
  (NOT-AG-22-048)
  National Institute on Aging
  National Cancer Institute
  National Heart, Lung, and Blood Institute
  National Institute on Minority Health and Health Disparities
  National Institute of Nursing Research
  Office of Research on Women's Health
  

• Notice of Special Interest (NOSI): Administrative Supplements for R25 Data Science Training for Infectious and Immune-mediated Disease Research
  (NOT-AI-23-010)
  National Institute of Allergy and Infectious Diseases
  National Cancer Institute
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Mental Health
  

• Notice of Special Interest (NOSI): Administrative Supplement for Rapid Translation of Substance Use and Addiction Epidemiology and Prevention Intervention Research
  (NOT-DA-24-003)
  National Institute on Drug Abuse
  

• Notice of Special Interest: Administrative Supplements to Promote Research Continuity and Retention of NIH Mentored Career Development (K) Award Recipients and Scholars
  (NOT-OD-23-031)
  Office of Research on Women's Health
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  National Institute of General Medical Sciences
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research
  National Library of Medicine
  

• Notice of Special Interest (NOSI): Administrative Supplement for Continuity of Biomedical and Behavioral Research Among First-Time Recipients of NIH Research Project Grant Awards
  (NOT-OD-23-032)
  Office of Research on Women's Health
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  National Institute of General Medical Sciences
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research
  National Library of Medicine
  

Funding Opportunities

• Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed)
  (PAR-23-036)
  National Heart, Lung, and Blood Institute
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Multisite Clinical Research: Leveraging Network Infrastructure to Advance Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities (U01 Clinical Trial Optional)
  (PAR-23-037)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Office of Research on Women's Health
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required)
  (PAR-23-057)
  National Institute on Aging
  Application Receipt Date(s): January 07, 2026
  
  

• FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)
  (PAR-23-072)
  Food and Drug Administration
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
  (RFA-CA-23-002)
  National Cancer Institute
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
  (RFA-CA-23-003)
  National Cancer Institute
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
  (RFA-CA-23-004)
  National Cancer Institute
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
  (RFA-CA-23-005)
  National Cancer Institute
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)
  (RFA-CA-23-006)
  National Cancer Institute
  Application Receipt Date(s): Not Applicable
  
  

• Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)
  (RFA-CA-23-007)
  National Cancer Institute
  Application Receipt Date(s): Not Applicable
  
  

• Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trials Optional)
  (RFA-CA-23-008)
  National Cancer Institute
  Application Receipt Date(s): Not Applicable
  
  

• Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional)
  (RFA-CA-23-009)
  National Cancer Institute
  Application Receipt Date(s): Not Applicable
  
  

• Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)
  (RFA-CA-23-010)
  National Cancer Institute
  Application Receipt Date(s): Not Applicable
  
  

• Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional)
  (RFA-CA-23-011)
  National Cancer Institute
  Application Receipt Date(s): Not Applicable
  
  

• NIDDK Information Network Coordinating Unit: dkNET-CU (U24 Clinical Trial Not Allowed)
  (RFA-DK-22-017)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 31, 2023
  
  

• Fostering Research With Additional Resources and Development (FORWARD) Urology Centers (P20 Clinical Trial Not Allowed)
  (RFA-DK-22-027)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Novel Approaches to Support Therapeutic Development in Ultra-Rare Cancers (U01) Clinical Trial Optional
  (RFA-FD-23-008)
  Food and Drug Administration
  Application Receipt Date(s): February 27, 2023
  
  

• Evaluation of Oral Modified Release Dosage Forms to Support the Approval of Additional Strengths (U01) Clinical Trial Not Allowed
  (RFA-FD-23-013)
  Food and Drug Administration
  Application Receipt Date(s): March 15, 2023
  
  

• Designing and Performing a Virtual Bioequivalence Trial for Physiologically-Based Pharmacokinetic and other Mechanism-Based Models (U01) Clinical Trial Not Allowed
  (RFA-FD-23-016)
  Food and Drug Administration
  Application Receipt Date(s): February 15, 2023
  
  

• Population Pharmacokinetic Modeling of Systemic Pharmacokinetic Data to Inform Bioequivalence in Regional Lung Exposure (U01) Clinical Trial Not Allowed
  (RFA-FD-23-017)
  Food and Drug Administration
  Application Receipt Date(s): February 28, 2023
  
  

• Cooperative Agreement to Support Regulatory Research Related to the 2022 Prescription Drug User Fee Act and Biosimilar User Fee Act (U19) Clinical Trials Not Allowed.
  (RFA-FD-23-023)
  Food and Drug Administration
  Application Receipt Date(s): March 13, 2023
  
  

• Opportunities for Advancing Limb Regeneration Research (R01 Clinical Trial Not Allowed)
  (RFA-HD-24-004)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): July 27, 2023
  
  

• NIH Research Evaluation and Commercialization Hubs (REACH) Awards (U01 Clinical Trial Optional)
  (RFA-OD-23-002)
  National Institute of General Medical Sciences
  Application Receipt Date(s): February 09, 2023
  
  

• NIH Research Evaluation and Commercialization Hubs (REACH) Awards (U01 Clinical Trial Optional)
  (RFA-OD-23-005)
  National Institute of General Medical Sciences
  Application Receipt Date(s): February 09, 2023